title: The DRD2 TaqI-B polymorphism and its relationship to smoking abstinence and withdrawal symptoms.
abstract: The dopamine receptor D2 (DRD2) gene has polymorphisms that have been linked to regulation of the dopamine system and to an increased prevalence of smoking. The present study examined the relationship of the DRD2 TaqI-A and -B polymorphisms with short-term clinical outcome (abstinence and withdrawal symptoms), collected from daily (14 pre-quit and 42 post-quit) diary data among smokers (n=116) treated with the nicotine patch plus either venlafaxine or placebo. The results showed that B1/B1 or B1/B2 smokers were slightly less likely to be abstinent on a given day than those homozygous for the TaqI-B2 allele. Significant DRD2 TaqI-B x time interactions were found for several of the withdrawal scales, indicating that those smokers with the B1/B1 or B1/B2 genotypes tended to report more symptoms over time compared to those with the B2/B2 genotype. No interactions or main effects were found for the DRD2 TaqI-A polymorphism. The findings demonstrate that smokers homozygous for the TaqI-B2 allele experience progressive improvement in self-reported withdrawal symptoms while smokers with the TaqI-B1 allele showing little change.
authors.affiliation: Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77230-1439, USA. jdrobinson@mdanderson.org
authors.forename: J D
authors.initials: JD
authors.lastname: Robinson
authors.forename: C Y
authors.initials: CY
authors.lastname: Lam
authors.forename: J A
authors.initials: JA
authors.lastname: Minnix
authors.forename: D W
authors.initials: DW
authors.lastname: Wetter
authors.forename: G E
authors.initials: GE
authors.lastname: Tomlinson
authors.forename: J D
authors.initials: JD
authors.lastname: Minna
authors.forename: T T-L
authors.initials: TT
authors.lastname: Chen
authors.forename: P M
authors.initials: PM
authors.lastname: Cinciripini
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use; D003511:Cyclohexanols / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006720:Homozygote; D006801:Humans; D015810:Linkage Disequilibrium; D008297:Male; D008875:Middle Aged; D009538:Nicotine / Q000008:administration & dosage; D018722:Nicotinic Agonists / Q000008:administration & dosage; D010641:Phenotype; D011110:Polymorphism, Genetic; D017448:Receptors, Dopamine D2 / Q000235:genetics* / Q000378:metabolism; D012720:Severity of Illness Index; D012907:Smoking / Q000235:genetics* / Q000378:metabolism; D016540:Smoking Cessation / Q000379:methods*; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D013997:Time Factors; D000069470:Venlafaxine Hydrochloride
chemical_list: D018687:Antidepressive Agents, Second-Generation; D003511:Cyclohexanols; D018722:Nicotinic Agonists; D017448:Receptors, Dopamine D2; D009538:Nicotine; D000069470:Venlafaxine Hydrochloride